Program
olomorasib
Also written as “Olomorasib”, “LY3537982” and “[¹⁴C]-LY3537982”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Renal Insufficiency · Hepatic Insufficiency, led by 3 companies.
Drug pageOlomorasib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 145 open or running | phase 3since Nov 1, 2023 | Jul 2, 2021 | Apr 2027phase 2 · NCT04956640 |
| Daiichi Sankyoits history only | 11 open or running | phase 2since Oct 16, 2026 | Oct 16, 2026 | Sep 30, 2029phase 2 · NCT07890714 |
| Johnson & Johnsonits history only | 11 open or running | phase 2since Nov 10, 2025 | Nov 10, 2025 | Nov 30, 2028phase 2 · NCT07227025 |
- Named in Eli Lilly’s own pipeline as
Olomorasib
, phase 3, as of Oct 29, 2026 (source).
Also a collaborator on its studies: AstraZeneca and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 2, 2021First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT04956640 · 540 enrolled · United States, Australia, Canada and more
- Apr 11, 2023Phase 1 study in HealthyNCT05824858 · 48 enrolled · United States
- Jun 4, 2023Phase 1 study in HealthyNCT05901311 · 16 enrolled · United States
- Oct 27, 2023Phase 1 study in HealthyNCT06111521 · 35 enrolled · United States
- Nov 1, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06119581 · 1,264 planned · United States, Australia, Austria and more
- Jan 24, 2024Phase 1 study in Advanced Solid TumorsNCT06235983 · 12 enrolled · China
- Aug 11, 2024Named olomorasibINNProposed as its International Nonproprietary Name in WHO's List 131 · before, LY3537982
- Dec 2, 2024Phase 1 study in Hepatic InsufficiencyNCT06719128 · 46 enrolled · United States
- Mar 18, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06890598 · 700 planned · United States, Australia, Austria and more
- Jun 26, 2025Phase 1 study in HealthyNCT07044271 · 120 enrolled · United States
- Aug 13, 20252 phase 1 studiesNCT07124013, NCT07137689
- Feb 24, 2026Phase 1 study in HealthyNCT07439250 · 15 enrolled · United States
- Aug 26, 2026Phase 1 study in Healthy VolunteersNCT07794592 · 24 planned · United States
- Sep 4, 2026Phase 2 study in Colorectal NeoplasmsNCT07814417 · 50 planned · United States, China, Spain
Ahead
- Apr 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT04956640
- Nov 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06119581
- Nov 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT07814417
- May 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06890598
TargetBeta
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, olomorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, …”NCIt, read by Claude
“An orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| KRAS G12D Inhibitor HRS-4642 | Jiangsu HengRui Medicine | phase 3 | 7 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 14 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07814417Colorectal Neoplasms · United States, China, Spain | 2 | Not yet recruiting | Nov 2028 | 50 |
| NCT07794592Healthy Volunteers · United States | 1 | Recruiting | Oct 2026 | 24 |
| NCT07439250Healthy · United States | 1 | Completed | Apr 17, 2026 | 15 |
| NCT07137689Renal Insufficiency · United States | 1 | Completed | Apr 10, 2026 | 32 |
| NCT07124013Healthy · Japan | 1 | Completed | Jan 5, 2026 | 191 |
| NCT07044271Healthy · United States | 1 | Completed | Nov 8, 2025 | 120 |
| NCT06890598Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | May 2029 | 700 |
| NCT06719128Hepatic Insufficiency · United States | 1 | Completed | Aug 25, 2025 | 46 |
| NCT06235983Advanced Solid Tumors · China | 1 | Completed | Jul 2, 2025 | 12 |
| NCT06119581Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Recruiting | Nov 2027 | 1,264 |
| NCT06111521Healthy · United States | 1 | Completed | Apr 1, 2024 | 35 |
| NCT05901311Healthy · United States | 1 | Completed | Aug 10, 2023 | 16 |
| NCT05824858Healthy · United States | 1 | Completed | Jun 17, 2023 | 48 |
| NCT04956640Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 2027 | 540 |
How it is read
Names in the registry
- “Olomorasib”, 8 entries
- “LY3537982”, 7 entries
- “[¹⁴C]-LY3537982”, 2 entries
- “Olomorasib test”, 1 entry
- “Olomorasib reference”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Colorectal Neoplasms, 1 study
- Renal Insufficiency, 1 study
- Hepatic Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.